Trending Stock News

Crown Crafts, Inc. (CRWS) Analysts See $0.20 EPS; Summit Therapeutics plc (SMMT) Had 6 Bulls

Analysts expect Crown Crafts, Inc. (NASDAQ:CRWS) to report $0.20 EPS on February, 21.They anticipate $0.01 EPS change or 5.26% from last quarter’s $0.19 EPS. CRWS’s profit would be $2.02 million giving it 8.13 P/E if the $0.20 EPS is correct. After having $0.07 EPS previously, Crown Crafts, Inc.’s analysts see 185.71% EPS growth. The stock increased 1.43% or $0.09 during the last trading session, reaching $6.5. About 11,629 shares traded. Crown Crafts, Inc. (NASDAQ:CRWS) has declined 14.68% since February 13, 2017 and is downtrending. It has underperformed by 31.38% the S&P500.

Among 7 analysts covering Summit Therapeutic (NASDAQ:SMMT), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Summit Therapeutic had 11 analyst reports since August 19, 2015 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Thursday, June 15. The company was maintained on Thursday, June 22 by Oppenheimer. The firm has “Buy” rating by Janney Capital given on Tuesday, June 21. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, November 16. The rating was maintained by Oppenheimer with “Buy” on Wednesday, August 19. As per Friday, December 1, the company rating was reinitiated by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $2600 target in Thursday, July 6 report. H.C. Wainwright initiated it with “Buy” rating and $26 target in Friday, September 16 report. The firm has “Outperform” rating given on Friday, January 26 by Oppenheimer. The stock of Summit Therapeutics plc (NASDAQ:SMMT) earned “Hold” rating by Zacks on Tuesday, September 1. See Summit Therapeutics plc (NASDAQ:SMMT) latest ratings:

26/01/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Outperform Old Target: $24 New Target: $30 Maintain
04/01/2018 Broker: SunTrust Rating: Buy New Target: $24 Initiates Coverage On
01/12/2017 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $16 Reinitiate

The stock increased 1.89% or $0.2 during the last trading session, reaching $10.8. About 23,001 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 33.22% since February 13, 2017 and is uptrending. It has outperformed by 16.52% the S&P500.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $158.61 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

Investors sentiment increased to 1.38 in 2017 Q3. Its up 0.11, from 1.27 in 2017Q2. It increased, as 6 investors sold Crown Crafts, Inc. shares while 7 reduced holdings. 8 funds opened positions while 10 raised stakes. 4.22 million shares or 0.64% more from 4.19 million shares in 2017Q2 were reported. Wells Fargo And Com Mn reported 98,022 shares. Geode Capital Management Lc holds 11,112 shares. Raymond James Associates holds 0% or 27,800 shares in its portfolio. Moreover, Tower Ltd Llc (Trc) has 0% invested in Crown Crafts, Inc. (NASDAQ:CRWS). Wellington Mngmt Group Inc Limited Liability Partnership holds 945,852 shares. 2,761 are held by Morgan Stanley. Blackrock accumulated 28,912 shares. Financial Bank Of America Corp De, a North Carolina-based fund reported 30 shares. Royal Savings Bank Of Canada reported 0% of its portfolio in Crown Crafts, Inc. (NASDAQ:CRWS). Renaissance Tech Limited Com owns 286,800 shares. Moab Cap Prns Limited Com invested in 652,288 shares. North Star Management reported 548,254 shares stake. Synovus Financial holds 0.01% in Crown Crafts, Inc. (NASDAQ:CRWS) or 118,863 shares. Dimensional Fund Advisors Ltd Partnership owns 36,047 shares. First Republic Inv Incorporated holds 0% or 64,058 shares in its portfolio.

Crown Crafts, Inc., through its subsidiaries, operates in the consumer products industry in the United States and internationally. The company has market cap of $65.56 million. It provides infant, toddler, and juvenile products, including crib and toddler beddings; blankets and swaddle blankets; nursery and toddler accessories; room d??cors; reusable and disposable bibs; burp cloths; hooded bath towels and washcloths; reusable and disposable placemats and floor mats; disposable cup labels, toilet seat covers, and changing mats; and other infant, toddler, and juvenile soft goods. It has a 19.35 P/E ratio. The firm sells its products primarily to mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, Internet accounts, and wholesale clubs through a network of sales force and independent commissioned sales representatives.

Leave a Reply

Your email address will not be published. Required fields are marked *